Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Assets (2016 - 2025)

Historic Current Assets for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $429.1 million.

  • Iovance Biotherapeutics' Current Assets changed N/A to $429.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year change of. This contributed to the annual value of $457.0 million for FY2024, which is 4845.57% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Current Assets stood at $429.1 million for Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Current Assets peaked at $637.8 million during Q1 2023, and registered a low of $274.9 million during Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Current Assets value was $422.5 million (recorded in 2025), while the average stood at $423.3 million.
  • Data for Iovance Biotherapeutics' Current Assets shows a peak YoY increase of 4845.57% (in 2024) and a maximum YoY decrease of 3955.09% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Current Assets (Quarter) stood at $307.8 million in 2023, then skyrocketed by 48.46% to $457.0 million in 2024, then fell by 6.11% to $429.1 million in 2025.
  • Its Current Assets was $429.1 million in Q3 2025, compared to $422.5 million in Q2 2025 and $512.6 million in Q1 2025.